Collegium Pharmaceutical, Inc.
COLL
$34.87
-$0.82-2.30%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 796.33M | 780.57M | 757.07M | 707.01M | 664.28M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 796.33M | 780.57M | 757.07M | 707.01M | 664.28M |
| Cost of Revenue | 86.25M | 86.93M | 89.55M | 88.30M | 86.07M |
| Gross Profit | 710.08M | 693.64M | 667.51M | 618.71M | 578.22M |
| SG&A Expenses | 291.27M | 281.34M | 273.32M | 249.84M | 217.42M |
| Depreciation & Amortization | 221.89M | 221.89M | 221.89M | 207.22M | 186.26M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 599.41M | 590.16M | 584.77M | 545.36M | 489.75M |
| Operating Income | 196.92M | 190.40M | 172.30M | 161.65M | 174.53M |
| Income Before Tax | 108.24M | 92.62M | 80.85M | 53.00M | 65.07M |
| Income Tax Expenses | 33.29M | 29.75M | 22.41M | 16.73M | 21.17M |
| Earnings from Continuing Operations | 74.95 | 62.87 | 58.44 | 36.27 | 43.89 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 74.95M | 62.87M | 58.44M | 36.27M | 43.89M |
| EBIT | 196.92M | 190.40M | 172.30M | 161.65M | 174.53M |
| EBITDA | 422.37M | 416.48M | 398.49M | 373.08M | 364.82M |
| EPS Basic | 2.36 | 1.99 | 1.84 | 1.13 | 1.36 |
| Normalized Basic EPS | 2.61 | 2.36 | 1.89 | 1.73 | 2.11 |
| EPS Diluted | 1.68 | 1.71 | 1.60 | 1.03 | 1.21 |
| Normalized Diluted EPS | 2.08 | 1.90 | 1.54 | 1.41 | 1.71 |
| Average Basic Shares Outstanding | 127.12M | 126.83M | 127.25M | 127.94M | 128.56M |
| Average Diluted Shares Outstanding | 158.66M | 151.43M | 151.47M | 152.19M | 153.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |